Vesprini D - Search Results

1

Pathological predictors for site of local recurrence after radiotherapy for prostate cancer.

Chopra S, Toi A, Taback N, Evans A, Haider MA, Milosevic M, Bristow RG, Chung P, Bayley A, Morton G, Vesprini D, Warde P, Catton C, Ménard C. Chopra S, et al. Among authors: vesprini d. Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e441-8. doi: 10.1016/j.ijrobp.2011.05.035. Int J Radiat Oncol Biol Phys. 2012. PMID: 22284038

2

V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression.

Nam RK, Toi A, Vesprini D, Ho M, Chu W, Harvie S, Sweet J, Trachtenberg J, Jewett MA, Narod SA. Nam RK, et al. Among authors: vesprini d. Urology. 2001 Jan;57(1):199-204. doi: 10.1016/s0090-4295(00)00928-6. Urology. 2001. PMID: 11164181

3

HPC2 variants and screen-detected prostate cancer.

Vesprini D, Nam RK, Trachtenberg J, Jewett MA, Tavtigian SV, Emami M, Ho M, Toi A, Narod SA. Vesprini D, et al. Am J Hum Genet. 2001 Apr;68(4):912-7. doi: 10.1086/319502. Epub 2001 Mar 14. Am J Hum Genet. 2001. PMID: 11254449 Free PMC article.

4

Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.

Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprini D, Chu W, Ho M, Sweet J, Evans A, Toi A, Pollak M, Narod SA. Nam RK, et al. Among authors: vesprini d. Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1429-37. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 14693733 Clinical Trial.

5

Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies.

Bristow RG, Ozcelik H, Jalali F, Chan N, Vesprini D. Bristow RG, et al. Among authors: vesprini d. Radiother Oncol. 2007 Jun;83(3):220-30. doi: 10.1016/j.radonc.2007.04.016. Epub 2007 May 24. Radiother Oncol. 2007. PMID: 17531338 Review.

6

Improving observer variability in target delineation for gastro-oesophageal cancer--the role of (18F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

Vesprini D, Ung Y, Dinniwell R, Breen S, Cheung F, Grabarz D, Kamra J, Mah K, Mansouri A, Pond G, Brock K, Darling G, Knox J, Haider M, Wong RK. Vesprini D, et al. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):631-8. doi: 10.1016/j.clon.2008.06.004. Epub 2008 Aug 27. Clin Oncol (R Coll Radiol). 2008. PMID: 18755578

7

Prostate delineation using CT and MRI for radiotherapy patients with bilateral hip prostheses.

Rosewall T, Kong V, Vesprini D, Catton C, Chung P, Ménard C, Bayley A. Rosewall T, et al. Among authors: vesprini d. Radiother Oncol. 2009 Mar;90(3):325-30. doi: 10.1016/j.radonc.2008.11.015. Epub 2008 Dec 31. Radiother Oncol. 2009. PMID: 19121547

8

Stage I seminoma: what should a practicing uro-oncologist do in 2009?

Skliarenko J, Vesprini D, Warde P. Skliarenko J, et al. Among authors: vesprini d. Int J Urol. 2009 Jun;16(6):544-51. doi: 10.1111/j.1442-2042.2009.02296.x. Epub 2009 Apr 20. Int J Urol. 2009. PMID: 19453548 Review.

9

No role for routine chest radiography in stage I seminoma surveillance.

Tolan S, Vesprini D, Jewett MA, Warde PR, O'Malley M, Panzarella T, Sturgeon JF, Moore M, Tew-George B, Gospodarowicz MK, Chung PW. Tolan S, et al. Among authors: vesprini d. Eur Urol. 2010 Mar;57(3):474-9. doi: 10.1016/j.eururo.2009.06.029. Epub 2009 Jun 26. Eur Urol. 2010. PMID: 19577354

10

Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance.

Loblaw A, Zhang L, Lam A, Nam R, Mamedov A, Vesprini D, Klotz L. Loblaw A, et al. Among authors: vesprini d. J Urol. 2010 Nov;184(5):1942-6. doi: 10.1016/j.juro.2010.06.101. Epub 2010 Sep 17. J Urol. 2010. PMID: 20846681 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

168 results

Search Page

Filters